by telrheum | Apr 21, 2024 | Lupus, Malignancy
The article titled “Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases” by YoungEun Kim and colleagues focuses on the connection between rheumatologic diseases and myelodysplastic syndromes (MDS), a type of...
by telrheum | Apr 7, 2024 | Biologic Therapy, Rheumatoid Arthritis
This article discusses a phase 3 clinical trial on telitacicept, a drug designed to treat rheumatoid arthritis (RA) in patients who have not responded well to methotrexate (MTX). Telitacicept is a recombinant fusion protein that targets and neutralizes two molecules,...
by telrheum | Apr 6, 2024 | Vasculitis, Biologic Therapy, Remove term: eosinophilic granulomatosis with polyangiitis eosinophilic granulomatosis with polyangiitis
The MANDARA study explored how effective and safe benralizumab is compared to mepolizumab for treating Eosinophilic Granulomatosis with Polyangiitis (EGPA), a condition that typically requires long-term treatment with oral glucocorticoids and immunosuppressants. This...
by telrheum | Apr 6, 2024 | Biologic Therapy, Rheumatoid Arthritis, tumour necrosis factor inhibitors (TNFis)
This study, conducted by researchers from Yonsei University College of Medicine in South Korea, investigated the risk of cardiovascular events like heart attacks or strokes in patients with ankylosing spondylitis (AS), a type of arthritis affecting the spine. They...
by telrheum | Apr 6, 2024 | Biologic Therapy, Sjögren’s Syndrome
Dazodalibep (DAZ) is a special type of protein used to treat Sjögren’s disease, which affects the immune system. In a study, patients with this disease took DAZ or a placebo (a treatment with no active drug) to see how effective and safe DAZ is. The study was...
